secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0000719135-24-000013
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q4 revenue up 16% to $14.7M; net loss widens to $9.6M; FY2024 guidance implies potential revenue decline
--------------------------------------------------------------------------------

- Q4 2023 Advanced Energy revenue $12.1M (+15% YoY); net loss $9.6M ($0.28/shr) vs $6.0M ($0.17) a year ago.
- Full year 2023 total revenue $52.3M (+18%); net loss improved to $18.7M ($0.54/shr) from $23.2M ($0.67) in 2022.
- FY2024 guidance: revenue $49.7M-$52.9M (down 5% to up 1%); net loss $24.3M-$26.5M, wider than 2023's $18.7M loss.
- New $45M Perceptive credit facility closed Nov 2023; initial $37.5M funded, used to repay MidCap and $2.7M in fees.
- Appointed Matthew Hill as CFO effective Dec 4, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/0000719135-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/apyx-20240321.htm
  HTML page:      https://secwatch.observer/filing/0000719135-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer